IDN adoption timelines feel “slow” from the outside because internal governance is designed to reduce clinical and operational risk. The commercial opportunity is real, but the pacing is governed by committee cadence, evidence review, and implementation capacity.
A realistic adoption sequence
- Early awareness: pharmacy and service line leaders assess fit with protocols and system priorities.
- Formal evaluation: the drug or solution enters formulary and policy review pathways (often P&T and subcommittees).
- Decision and restrictions: approval frequently includes criteria and operational guardrails.
- Implementation: build, education, and supply chain integration. This is where conversion is won or lost.
- Scale: standardization across facilities takes time and requires sustained execution.
What the cadence tells you
Many P&T processes operate on monthly to quarterly cycles. Even when a product is clinically compelling, governance cadence sets a minimum clock. A large system may also require pre meetings, documentation packets, and cross functional signoff.
Field execution that matches the clock
Instead of chasing a premature “yes,” Vendxa aligns field activity to the actual decision pathway: right stakeholders at the right time, value story tied to operations, and a simple implementation plan that reduces the perceived burden on the system.